Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy

Trial Profile

A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABTL 0812 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Ability Pharmaceuticals
  • Most Recent Events

    • 04 Feb 2019 According to an Ability Pharmaceuticals media release, SciClone Pharmaceuticals (partner of Ability Pharmaceuticals in China) has obtained the approval from the Chinese medicine agency NMPA to start this trial in China with the anticancer product ABTL0812.This important milestone is the result of the collaboration between AbilityPharma and SciClone (May 2016) that granted an exclusive license to SciClone to develop and market ABTL0812 in China, Taiwan, Hong Kong, Macao and Vietnam.
    • 01 Feb 2019 Planned initiation date changed from 1 Apr 2019 to 1 Dec 2019.
    • 01 Feb 2019 Planned initiation date changed from 1 Apr 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top